Three Main Mutational Pathways in HIV-2 Lead to High-Level Raltegravir and Elvitegravir Resistance: Implications for Emerging HIV-2 Treatment Regimens

Human immunodeficiency virus type 2 (HIV-2) is intrinsically resistant to non-nucleoside reverse transcriptase inhibitors and exhibits reduced susceptibility to several of the protease inhibitors used for antiretroviral therapy of HIV-1. Thus, there is a pressing need to identify new classes of anti...

Descripción completa

Detalles Bibliográficos
Autores principales: Smith, Robert A., Raugi, Dana N., Pan, Charlotte, Coyne, Matthew, Hernandez, Alexandra, Church, Brad, Parker, Kara, Mullins, James I., Sow, Papa Salif
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3445448/
https://www.ncbi.nlm.nih.gov/pubmed/23028968
http://dx.doi.org/10.1371/journal.pone.0045372

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3445448/
https://www.ncbi.nlm.nih.gov/pubmed/23028968
http://dx.doi.org/10.1371/journal.pone.0045372

Ejemplares similares